



MICHAEL J MINZENBERG, MD

(925) 268-8211 | drminzenberg@canmi.org

PRIMARY AREAS OF EXPERTISE

Transcranial Magnetic Stimulation
Pharmacology
Major Depressive Disorder
Anxiety Disorders
Bipolar-Spectrum Disorders
Social/affective Neuroscience
Neuroimaging
Schizophrenia

PUBLICATIONS

74 total peer-reviewed articles
(35 first-author)
11 book chapters
21 articles with > 100 citations
Select and most recent peer-reviewed articles listed.

LICENSES/CERTIFICATION

Medical Licensure, California
1996
Medical Licensure, New York
2003
Board Certification, American Board of
Psychiatry and Neurology, Inc.
2002
Licensure, Drug Enforcement
Administration
1997

EDUCATION

Mount Sinai School of Medicine, NY
Research Fellowship Psychiatry, 2003-2005

University of California, San Francisco
Research Fellowship Psychiatry, 1999-2002

University of California, San Francisco
Residency Psychiatry, 1995-1999

McGill University, Montreal, Canada
M.D. Medicine, 1991-1995

Rutgers University, New Brunswick, NJ
M.S. Physiology and Neurobiology, 1985-1988

University of California, Davis
B.S. Zoology, 1981-1985

PROFESSIONAL EXPERIENCE

Associate Physician Diplomate, 2016-2019
UCLA Psychiatry
TMS clinical care · TMS-neuroscience research · teaching

Associate Professor, 2012-2016
UCSF School of Medicine
Staff Psychiatrist, General Psychiatry Outpatient Service, San
Francisco VA Medical Center
Clinical neuroscience research · outpatient pharmacology · teaching

Associate Professor, 2010-2012
UC Davis School of Medicine
Medical Director, Sac-EDAPT (First-Episode Psychosis) Clinic
Clinical neuroscience research · outpatient pharmacology · teaching

MICHAEL J MINZENBERG, MD

(925) 268-8211 | drminzenberg@canmi.org

PROFESSIONAL EXPERIENCE continued...

Assistant Professor, 2006-2010

UC Davis School of Medicine

Associate Director, Early Diagnosis and Preventative Treatment of Psychotic Disorders (EDAPT) Clinic Clinical neuroscience research · outpatient pharmacology · teaching

Private Practice, Oakland, CA, 2011-2016

Office-based practice specializing in pharmacotherapy for complex and treatment-resistant mood, anxiety and personality disorders; close case coordination with psychotherapist practitioners

Medical Director, 2014-Present

Gladman Mental Health Rehabilitation Center (Oakland)

Medical Director for subacute-care, locked inpatient Psychiatric MHRC

Medical Director, 2014-2019

Crestwood Behavioral Health -Solano (Vallejo)

Medical Director for acute-care, locked inpatient Psychiatric Health Facility

Prevention & Recovery in Early Psychosis (PREP) – SF, 2014-2018

Alameda and San Mateo counties (Family Service Agency, San Francisco, DBA Felton Institute). Early-intervention and multidisciplinary treatment in an evidence-based, recovery-oriented model of care.

MEMBERSHIPS

American Psychiatric Association, 2016-Present

Clinical TMS Society, 2018-Present

International Brain Stimulation Society, 2018-Present

Society of Biological Psychiatry, 2004-Present

Society for Neuroscience, 2006-Present

MICHAEL J MINZENBERG, MD

(925) 268-8211 | drminzenberg@canmi.org

OTHER SERVICE

Peer Reviewer for approximately 35 academic journals in clinical psychiatry, cognitive neuroscience, pharmacology and basic neuroscience, 2006- Present

Associate Scientific Advisor, Science Translational Medicine, 2010- 2011

Consultant, Korean Community Center of the East Bay, Oakland, CA, 2011 -Present

Hospital Bioethics Consultation Committee, UC Davis Medical Center, 2010 -2011

Member, Data Safety Monitoring Board (Dr. Steven Batki, PI), SFVAMC, 2013 -2016

Member, SFVAMC Clinical Research Workgroup (IRB), 2013 -2016

Member, Non-VA Care (VA Choice Program) Referral Service, 2014 -2016

SELECT & MOST RECENT PEER-REVIEWED PUBLICATIONS

Minzenberg MJ, Yoon JH (in press). Transcranial Magnetic Stimulation: A Clinical Primer for Non-Experts. *Journal of Psychiatric Practice*

Minzenberg MJ, Leuchter AF (2019). Modulation of cortical excitability and plasticity with transcranial magnetic stimulation: the effect of psychotropic drugs, and implications for psychiatric treatment. *Journal of Affective Disorders* 253:126-140.

Hunter AM, Minzenberg MJ (co-primary author), Cook IA, Krantz DE, Levitt JG, Rotstein NM, Chawla SA, Leuchter AF (2019). Concomitant medication use and clinical outcome of repetitive Transcranial Magnetic Stimulation treatment of Major Depressive Disorder. *Brain & Behavior* 9(5): e01275.

Corlier J, Burnette E, Wilson AC, Lou JJ, Landeros A, Minzenberg MJ, Leuchter AF (in review). Does Cognitive Control Improve Following Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Major Depressive Disorder (MDD)?

Levitt J, Kalender G, O'Neil J, Diaz JP, Vince-Cruz N, Nguyen LD, Cook IA, Ginder N, Krantz D, Minzenberg MJ, Alger JR, Leuchter AF (2019). Dorsolateral prefrontal gamma-aminobutyric acid in treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy. *Journal of Psychiatry and Neuroscience* 44(4):1-9.

Corlier J, Wilson A, Hunter AM, Vince-Cruz N, Krantz D, Levitt J, Minzenberg MJ, Ginder N, Cook IA, Leuchter AF (2019). Acute Changes in Neurophysiologic Connectivity Predict Outcome of Repetitive Transcranial Magnetic Stimulation Treatment of Major Depressive Disorder. *Cerebral Cortex* [Epub ahead of print].

Hunter AM, Nghiem TX, Cook IA, Krantz DE, Minzenberg MJ, Leuchter AF (2018). Change in Quantitative EEG Theta Cordance as a Potential Predictor of Repetitive Transcranial Magnetic Stimulation Clinical Outcome in Major Depressive Disorder. *Clin EEG Neurosci* 49(5):306-315.

Kobayashi B, Cook IA, Hunter AM, Minzenberg MJ, Krantz DE, Leuchter AF (2017). Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder? *Int Rev Psychiatry* 31:1-17.

MICHAEL J MINZENBERG, MD

(925) 268-8211 | drminzenberg@canmi.org

SELECT & MOST RECENT PEER-REVIEWED PUBLICATIONS continued...

- Minzenberg MJ, Carter CS (2007) The Quest for Developing New Treatments from Imaging Techniques: Promises, Problems and Future Potential. *Expert Opin Invest Drugs* 2(8): 1029-1033.
- Minzenberg MJ, Watrous AJ, Yoon JH, Ursu S, Carter CS (2008). Modafinil Shifts Human Locus Coeruleus to Low-Tonic, High-Phasic Activity During Functional MRI. *Science* 322(5908):1700-2.
- Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC (2009). Meta-Analysis of 41 Functional Neuroimaging Studies of Executive Function in Schizophrenia. *Archives of Gen Psychiatry* 66(8):811-22.
- Minzenberg MJ, Carter CS (2011). Developing Treatments for Impaired Cognition in Schizophrenia. *Trends in Cognitive Sciences* 16(1):35-42.
- Minzenberg MJ (2012). Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder: From Cells to Circuits. *Neurotherapeutics* 9(3):610-621.
- Minzenberg MJ, Poole JH, Benton C, Vinogradov S (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. *Am J Psychiatry* 161(1): 116-24.
- Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, Ragland JD, Solomon M, Carter CS (2015). A Multimodal Analysis of Antipsychotic Effects on Brain Structure and Function in First-Episode Schizophrenia. *JAMA Psychiatry* 72(3):226-234.